Biophytis Launches Phase 2 Obesity Trial for Sarconeos
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, biotechnology
TL;DR
Biophytis just kicked off a Phase 2 obesity trial for Sarconeos (BIO101) - big news for their pipeline!
AI Summary
Biophytis S.A. announced on April 8, 2025, the launch of its Phase 2 OBA clinical trial for obesity. The trial aims to evaluate the efficacy and safety of Sarconeos (BIO101) in treating obesity and related complications. This marks a significant step in the company's development pipeline for its lead drug candidate.
Why It Matters
This trial could validate Sarconeos as a treatment for obesity, a widespread condition with significant health and economic impacts, potentially opening a new market for Biophytis.
Risk Assessment
Risk Level: medium — Clinical trial success is inherently uncertain, and Phase 2 trials carry significant risks of failure to demonstrate efficacy or safety.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Sarconeos (BIO101) (drug) — Investigational drug
- Stanislas Veillet (person) — Contact person
- April 8, 2025 (date) — Press release date
- Phase 2 OBA Clinical Trial (trial) — Clinical trial name
FAQ
What is the primary objective of the Phase 2 OBA clinical trial?
The trial aims to evaluate the efficacy and safety of Sarconeos (BIO101) in treating obesity and related complications.
What is the name of the drug being tested in the OBA trial?
The drug being tested is Sarconeos, also known as BIO101.
When was the press release announcing the trial launch issued?
The press release was issued on April 8, 2025.
What is the principal executive office address for Biophytis S.A.?
The address is Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75005 Paris, France.
Does Biophytis S.A. file annual reports under Form 20-F or 40-F?
Biophytis S.A. indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 9, 2025 by Stanislas Veillet regarding Biophytis SA.